Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$53.77 USD
-1.83 (-3.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $53.79 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 615 | 783 | 472 | 464 | 225 |
Receivables | 1 | 0 | 52 | 4 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 12 | 12 | 6 | 3 |
Total Current Assets | 628 | 795 | 536 | 474 | 234 |
Net Property & Equipment | 69 | 80 | 73 | 13 | 5 |
Investments & Advances | 41 | 47 | 152 | 37 | 43 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 10 | 7 | 0 | 0 |
Total Assets | 824 | 1,015 | 841 | 534 | 290 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 22 | 26 | 21 | 8 | 8 |
Current Portion Long-Term Debt | 10 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 43 | 44 | 34 | 19 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 2 | 2 | 1 | 1 |
Total Current Liabilities | 103 | 85 | 72 | 31 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 87 | 87 | 0 |
Convertible Debt | 549 | 546 | 95 | 90 | 84 |
Long-Term Debt | 58 | 64 | 47 | 46 | 45 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 380 | 302 | 184 | 166 | 143 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,211 | 1,123 | 597 | 420 | 301 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,726 | 1,482 | 1,452 | 1,105 | 853 |
Retained Earnings | -2,112 | -1,586 | -1,208 | -992 | -865 |
Other Equity | 0 | -4 | -1 | 0 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -386 | -108 | 244 | 113 | -11 |
Total Liabilities & Shareholder's Equity | 824 | 1,015 | 841 | 534 | 290 |
Total Common Equity | -386 | -108 | 244 | 113 | -11 |
Shares Outstanding | 98.00 | 94.60 | 83.80 | 70.70 | 59.00 |
Book Value Per Share | -3.94 | -1.14 | 2.91 | 1.60 | -0.19 |
Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,057 | 619 | 615 | 539 | 566 |
Receivables | 0 | 1 | 1 | 3 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 19 | 12 | 20 | 20 |
Total Current Assets | 1,068 | 639 | 628 | 561 | 587 |
Net Property & Equipment | 66 | 68 | 69 | 76 | 77 |
Investments & Advances | 305 | 15 | 41 | 15 | 27 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 8 | 8 | 8 | 8 |
Total Assets | 1,524 | 808 | 824 | 741 | 780 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 13 | 22 | 14 | 13 |
Current Portion Long-Term Debt | 12 | 12 | 10 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 40 | 40 | 43 | 33 | 31 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 23 | 6 | 11 | 14 | 6 |
Total Current Liabilities | 103 | 89 | 103 | 78 | 66 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 551 | 550 | 549 | 548 | 547 |
Long-Term Debt | 93 | 57 | 58 | 61 | 62 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 552 | 380 | 370 | 314 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,415 | 1,204 | 1,211 | 1,179 | 1,113 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,501 | 1,852 | 1,726 | 1,537 | 1,514 |
Retained Earnings | -2,391 | -2,248 | -2,112 | -1,975 | -1,846 |
Other Equity | -1 | -1 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 109 | -396 | -386 | -439 | -333 |
Total Liabilities & Shareholder's Equity | 1,524 | 808 | 824 | 741 | 780 |
Total Common Equity | 109 | -396 | -386 | -439 | -333 |
Shares Outstanding | 104.80 | 104.50 | 98.00 | 96.00 | 95.60 |
Book Value Per Share | 1.04 | -3.79 | -3.94 | -4.57 | -3.48 |